Skip to main navigation
Menu
  • Focus & Strategy
  • Innovation & Pipeline
  • Disease Areas
  • Investors & Media
  • Contact
Focus & Strategy
  • President’s Letter
  • Leadership
  • Board of Directors
Innovation & Pipeline
  • Roluperidone (MIN-101)
  • Seltorexant (MIN-202)
  • MIN-301
Disease Areas
  • Schizophrenia
  • Insomnia and Mood Disorders
  • Parkinson’s Disease
Investors & Media
  • Press Releases
  • Events & Presentations
  • Corporate Governance
  • Financials & Filings
  • Stock Information
  • Investor FAQs
  • Contact Us
Corporate Governance
  • Executive Management
  • Board of Directors
  • Committee Composition
  • Contact the Board
Financials & Filings
  • SEC Filings
  • Annual Reports and Proxies
  • Quarterly Results
  • Key Ratios
Stock Information
  • Historic Stock Lookup
  • Investment Calculator
  • Analyst Coverage
Minerva Neurosciences logo
  • Focus & Strategy
    • President’s Letter
    • Leadership
    • Board of Directors
  • Innovation & Pipeline
    • Roluperidone (MIN-101)
    • Seltorexant (MIN-202)
    • MIN-301
  • Disease Areas
    • Schizophrenia
    • Insomnia and Mood Disorders
    • Parkinson’s Disease
  • Investors & Media
    • Press Releases
    • Events & Presentations
    • Corporate Governance
      • Executive Management
      • Board of Directors
      • Committee Composition
      • Contact the Board
    • Financials & Filings
      • SEC Filings
      • Annual Reports and Proxies
      • Quarterly Results
      • Key Ratios
    • Stock Information
      • Historic Stock Lookup
      • Investment Calculator
      • Analyst Coverage
    • Investor FAQs
    • Contact Us
  • Contact

INVESTORS & MEDIA

  • Press Releases
  • Events & Presentations
  • Corporate Governance
    • Executive Management
    • Board of Directors
    • Committee Composition
    • Contact the Board
  • Financials & Filings
  • Stock Information
  • Investor FAQs
  • Contact Us

Shareholder Tools

Printed Materials
Email Alerts
Downloads
RSS
Print
Share

  • RSS

Board of Directors

  • Remy Luthringer, Ph.D.

    • William F. Doyle

      • Chair of the Compensation Committee
      • Member of the Audit Committee
    • Hans Peter Hasler

      • Member of the Compensation Committee
      • Member of the Nominating and Governance Committee
    • Jan van Heek

      • Member of the Audit Committee
    • Jeryl Hilleman

      • Chair of the Audit Committee
    • David Kupfer, M.D.

      • Chair of the Nominating and Governance Committee
    • Fouzia Laghrissi-Thode, M.D.

      • Member of the Compensation Committee

    Shareholder Tools

    Printed Materials
    Email Alerts
    Downloads
    RSS
    Print
    Share

    • RSS
  • About Us

    • President's Letter
    • Leadership
    • Board of Directors
  • Disease Areas

    • Schizophrenia
    • Insomnia and Mood Disorders
    • Parkinson’s Disease
  • Innovation & Pipeline

    • Roluperidone (MIN-101)
    • Seltorexant (MIN-202)
    • MIN-301
  • (617) 600-7373
    email us
    Privacy Policy | Terms of Use

    Biotech Web Design Company ©2017 Minerva Neurosciences